Velocity Clinical Research has made three investments in technology to extend patient community, boost client engagement in trials, and expedite the development of therapies in its 30 integrated locations.
The company randomised 25,000 subjects into Phase II and III clinical trials in the US in the last 12 months.
Investing in technology will aid Velocity to identify patients and enhance the participation frequency in trials.
Initially, Velocity collaborated with Advarra on a regulatory and compliance technology rollout.
This partnership leverages Advarra’s Clinical Conductor Enterprise-level clinical trial management system (CTMS) integrated with eReg and eSource, for accessing more than 500,000 patients’ data in its national site network.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Under the second investment, Master Control will offer its Quality Management System (QMS).
With the development, patients and sponsor partners of Velocity will profit from its improved expertise to back new innovations, enhance quality and compliance and facilitate improved site efficiency attained using automated quality processes.
Furthermore, the company acquired a secure platform called TrierHealth that permits digital clinical trial execution.
The research and development (R&D) team of TrierHealth works in the Indian city of Hyderabad for developing patient-centred technology that leverages artificial intelligence and data science to boost clinical research.
With the latest development, TrierHealth founder Raghu Punnamraju will join Velocity as chief technology officer.
Velocity Clinical Research chief executive and president Dr G Paul Evans said, “We’re building a global community of patients who are engaged, advocate for participation in clinical research, and actively take part in multiple studies.
“Velocity is setting a new standard of integration for the research site industry to better recruit and retain patients into clinical research.”
In April last year, Global Healthcare Opportunities (GHO Capital) entered an agreement for the acquisition of Velocity Clinical Research.
